the second and third quarters of 2007, respectively.
(f) Purchase of in-process research and development during the nine
months ended September 30, 2007 includes a write-off of $169.0
million associated with the value of in-process research and
development costs incurred in connection with our acquisition of
(g) Charges totaling $15.6 million associated with the write-off of debt
origination costs and a prepayment premium paid upon early
extinguishment of related debt during the nine months ended
September 30, 2007, in conjunction with our financing arrangements.
(h) A $1.7 million net realized foreign currency loss associated with a
cash escrow established in connection with the acquisition of BBI
(i) A $1.9 million foreign currency gain realized on the settlement of
(j) Tax effect on adjustments as discussed above in notes (b), ( c ),
(d), (e), (f), (g), (h) and (i).
(k) For the nine months ended September 30, 2008 and 2007, potential
dilutive shares were not used in the calculation of diluted net loss
per common share under GAAP because inclusion thereof would be
(l) Included in the weighted average diluted common shares for the
calculation of net income per common share for the nine months ended
September 30, 2008, on an adjusted cash basis, are dilutive shares
consisting of 2,349,000 common stock equivalent shares from the
potential exercise of stock options and warrants and potential
dilutive shares consisting of 3,411,000 common stock equivalent
shares from the potential conversion of convertible debt securities.
The net income per dilute
|SOURCE Inverness Medical Innovations, Inc.|
Copyright©2008 PR Newswire.
All rights reserved